by | Jan 20, 2023 | Oh, Youngmi, Yoo, Andrew
— Technology Description
Researchers in Andrew Yoo’s laboratory at Washington University have developed an antisense oligonucleotide targeting a miRNA (miR-29b-3p) as a treatment for Huntington’s disease (HD). Inhibiting miR-29b-3p promotes neuronal survival by rescuing neurons from deg…
by | Jul 18, 2022 | Benzinger, Tammie, Guzman, Gloria, Wang, Qing, Wang, Yong
— Background
Currently, biopsies are the only definitive method to diagnose a brain tumor. While PET-CT is used for initial imaging and monitoring of the tumor, after completion of treatments, a 6-8-week delay is usually implemented to avoid false-positive results. Yet, the delay could also result in…
by | Jul 18, 2022 | Benzinger, Tammie, Guzman, Gloria, Wang, Qing, Wang, Yong
— Background
Currently, biopsies are the only definitive method to diagnose a brain tumor. While PET-CT is used for initial imaging and monitoring of the tumor, after completion of treatments, a 6-8-week delay is usually implemented to avoid false-positive results. Yet, the delay could also result in…
by | Jun 28, 2022 | Klein, Robyn, Williams, Jessica
— Technology Description
Researchers in Prof. Robyn Klein’s laboratory have discovered that interferon lambda (IFN-λ) is a potential target for treating multiple sclerosis (MS), particularly secondary progressive MS (SPMS).
Most patients with MS present with relapsing remitting MS (RRM…
by | Mar 3, 2022 | Yablonskiy, Dmitriy, Zhao, Yue
— Technology Description
Researchers in Prof. Dmitriy Yablonskiy’s laboratory have developed patented neuroimaging techniques to identify pre-clinical and early stage Alzheimer’s disease (AD) using MRI-based biomarkers of amyloid accumulation and other pathological changes in the brain. …